1. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease
- Author
-
Mahadevan, Uma, Long, Millie D, Kane, Sunanda V, Roy, Abhik, Dubinsky, Marla C, Sands, Bruce E, Cohen, Russell D, Chambers, Christina D, Sandborn, William J, and Alliance, Crohn’s Colitis Foundation Clinical Research
- Subjects
Preterm ,Low Birth Weight and Health of the Newborn ,Clinical Research ,Infant Mortality ,Contraception/Reproduction ,Digestive Diseases ,Pediatric ,Inflammatory Bowel Disease ,Prevention ,Perinatal Period - Conditions Originating in Perinatal Period ,Conditions Affecting the Embryonic and Fetal Periods ,Reproductive health and childbirth ,Good Health and Well Being ,Adult ,Anti-Inflammatory Agents ,Azathioprine ,Biological Products ,Colitis ,Ulcerative ,Crohn Disease ,Drug Therapy ,Combination ,Female ,Humans ,Infant ,Newborn ,Intestinal Mucosa ,Mercaptopurine ,Pregnancy ,Pregnancy Complications ,Pregnancy Outcome ,Prenatal Exposure Delayed Effects ,Prospective Studies ,United States ,Crohn's Disease ,Ulcerative Colitis ,Crohn’s Colitis Foundation Clinical Research Alliance ,Crohn’s Disease ,Clinical Sciences ,Neurosciences ,Paediatrics and Reproductive Medicine ,Gastroenterology & Hepatology - Abstract
Background & aimsPregnant women with inflammatory bowel disease (IBD) may require biologic or thiopurine therapy to control disease activity. Lack of safety data has led to therapy discontinuation during pregnancy, with health repercussions to mother and child.MethodsBetween 2007 and 2019, pregnant women with IBD were enrolled in a prospective, observational, multicenter study across the United States. The primary analysis was a comparison of 5 outcomes (congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infant infections) among pregnancies exposed vs unexposed in utero to biologics, thiopurines, or a combination. Bivariate analyses followed by logistic regression models adjusted for relevant confounders were used to determine the independent effects of specific drug classes on outcomes of interest.ResultsAmong 1490 completed pregnancies, there were 1431 live births. One-year infant outcomes were available in 1010. Exposure was to thiopurines (n = 242), biologics (n = 642), or both (n = 227) vs unexposed (n = 379). Drug exposure did not increase the rate of congenital malformations, spontaneous abortions, preterm birth, low birth weight, and infections during the first year of life. Higher disease activity was associated with risk of spontaneous abortion (hazard ratio, 3.41; 95% confidence interval, 1.51-7.69) and preterm birth with increased infant infection (odds ratio, 1.73; 95% confidence interval, 1.19-2.51).ConclusionsBiologic, thiopurine, or combination therapy exposure during pregnancy was not associated with increased adverse maternal or fetal outcomes at birth or in the first year of life. Therapy with these agents can be continued throughout pregnancy in women with IBD to maintain disease control and reduce pregnancy-related adverse events. ClinicalTrials.gov, Number: NCT00904878.
- Published
- 2021